We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

KWR:NYSEQuaker Houghton Analysis

Data as of 2026-06-07 - not real-time

$140.69

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

KWR is trading near its 20‑day moving average, indicating a neutral price stance. The stock sits above its 50‑day SMA but below the 200‑day SMA, suggesting limited upward momentum. Technicals show a bearish MACD histogram and a decreasing volume trend, which dampens short‑term optimism. Support rests around the low‑130 level while resistance hovers near the mid‑150 range, framing a relatively tight trading corridor. The 30‑day volatility is elevated, reflecting price swings that exceed typical market moves. With a beta above one, the equity is more sensitive to broader market fluctuations.
Fundamentally, the company reports modest revenue growth and a solid gross margin for a specialty chemical player. Profitability is thin, with a profit margin barely above zero and a low ROE, underscoring earnings fragility. The trailing PE is astronomically high, while the forward PE contracts to a more reasonable level, highlighting expectations of accelerating earnings. The DCF fair‑value estimate is substantially below the current market price, pointing to a clear overvaluation gap. Dividend yield is modest but the payout ratio is extremely low, making the dividend appear sustainable under current cash flow. Analyst consensus is neutral with no strong recommendation, aligning with the mixed technical and fundamental signals.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • price near support level
  • bearish MACD histogram
  • decreasing trading volume

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • forward earnings upside
  • more reasonable forward PE
  • sustainable dividend payout

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • persistent overvaluation relative to DCF
  • thin profit margins
  • moderate sector cyclicality

Key Metrics & Analysis

Financial Health

Revenue Growth8.50%
Profit Margin0.22%
P/E Ratio562.8
ROE0.32%
ROA4.34%
Debt/Equity65.95
P/B Ratio1.8
Op. Cash Flow$143.3M
Free Cash Flow$108.4M

Technical Analysis

TrendNeutral
RSI49.8
Support$130.36
Resistance$150.58
MA 20$141.95
MA 50$136.45
MA 200$140.11
MACDBearish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Fair Value$75.55
Target Price$169.50
Upside/Downside20.48%
GradeOvervalued
TypeBlend
Dividend Yield1.44%

Risk Assessment

Beta1.30
Volatility36.72%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.